Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration
Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration
复制标题
DOI：
10.1007/s00417-013-2505-2
复制
发表时间：
2013-06
期刊：
影响因子：
--
通讯作者：
Xiying Wang;T. Sawada;Masashi Kakinoki;Taichiro Miyake;H. Kawamura;Y. Saishin;Ping Liu;M. Ohji
中科院分区：
文献类型：
--
作者：
Xiying Wang;T. Sawada;Masashi Kakinoki;Taichiro Miyake;H. Kawamura;Y. Saishin;Ping Liu;M. Ohji
目的探讨老年性黄斑变性(AMD)患者玻璃体内注射雷尼比单抗(IVR)后1个月和2个月的血清血管内皮生长因子(VEGF)和雷尼比单抗浓度变化。9只眼每月注射3次，17只眼每两个月注射2次。结果第一次注射后1个月9只眼中8只眼和第二次注射后1个月后9只眼中7只眼房水中血管内皮生长因子浓度降至最低可检测限值以下(P<； 0.001，平均基线值94.7pg/ml)，双月注射组17只眼中2只眼首次注射后2个月房水中血管内皮生长因子浓度降至最低可检测限值以下(P<； 0.001，平均基线值152.4 pg/ml)。第一次注射后1个月的平均浓度为71.2 ng/ml，第二次注射后1个月的平均浓度为96.3 ng/ml。双月注射组17只眼中15只眼房水中雷尼比珠单抗平均浓度为2.5 ng/ml，首次注射2个月后有2只眼房水浓度低于最低检测限值。结论在这项随访有限的先导性研究中，大多数病例玻璃体腔内注射雷尼比单抗可完全抑制房水中的血管内皮生长因子1个月。在大多数情况下，它的作用不足以完全抑制VEGF，尽管在大多数情况下，玻璃体内注射雷尼比单抗后2个月的房水中的VEGF比注射前的要少。
PurposeTo evaluate vascular endothelial growth factor (VEGF) and ranibizumab concentrations in eyes with age-related macular degeneration (AMD) after monthly and bimonthly intravitreal ranibizumab (IVR) injections.MethodsAqueous humor samples were obtained from 26 eyes with AMD before and after IVR injections. Nine eyes received three monthly injections and 17 eyes received two bimonthly injections. The VEGF and ranibizumab concentrations were measured by enzyme-linked immunosorbent assay.ResultsThe aqueous VEGF concentrations in the monthly injection group decreased below the lowest detectable limit in eight of nine eyes 1 month after the first injection and seven of nine eyes 1 month after the second injection (P< 0.001, mean baseline value, 94.7 pg/ml); the aqueous VEGF concentrations in the bimonthly injection group decreased below the lowest detectable limit in two of 17 eyes 2 months after the first injection (P< 0.001, mean baseline value, 152.4 pg/ml). The mean aqueous ranibizumab concentrations with monthly injections were 71.2 ng/ml 1 month after the first injection, and 96.3 ng/ml 1 month after the second injection. The mean aqueous ranibizumab concentrations in the bimonthly injection group were 2.5 ng/ml in 15 of 17 eyes, and below the lowest detectable limit in two of 17 eyes 2 months after the first injection.ConclusionsIn this pilot study with limited follow-up, intravitreal injection of ranibizumab can suppress aqueous VEGF completely for 1 month in most cases. Its effect does not last for 2 months enough to suppress VEGF completely in most cases, although aqueous VEGF at 2 months after intravitreal injection of ranibizumab is less than that before injection in most cases.